Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim concerns the generic name relationship between suvorexant and Belsomra. The supplied FDA label excerpts explicitly show BELSOMRA (suvorexant), supporting that suvorexant is the active ingredient/generic name for the brand Belsomra.
Category Scores
Accurate Statements
Suvorexant is the generic name (INN) for the insomnia medication marketed under brand names such as Belsomra.
Label section text uses the construction “BELSOMRA® (suvorexant)”, directly indicating suvorexant is the labeled ingredient/denomination associated with the Belsomra brand (1 INDICATIONS AND USAGE and drug labeling header).
Unsupported Statements
Suvorexant is the generic name (INN) for the insomnia medication marketed under brand names such as Belsomra.
The excerpt provided shows “BELSOMRA® (suvorexant)” but does not explicitly state the term “INN” or “generic name” wording, nor does it list other brand names beyond BELSOMRA.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim is about naming/ingredient association and does not make dosing, safety, or use-eligibility assertions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Label excerpts support “BELSOMRA (suvorexant)” but do not explicitly use the phrasing “generic name (INN)” or mention other brand names.
Suggested Improvement
Rephrase to align with the label’s wording, e.g., “BELSOMRA® (suvorexant)…” without asserting “INN” or additional brands unless provided in the label.